$ONC News

BeOne Medicines: Owning The Full B-Cell Treatment Sequence

JP Morgan Maintains Overweight on BeOne Medicines, Raises Price Target to $425

BeOne Medicines Announces $300M Expansion Of Its Manufacturing And R&D Center In New Jersey; Total U.S. Manufacturing Investment Reaches $1B+

Barclays Maintains Overweight on BeOne Medicines, Lowers Price Target to $403

Jefferies Upgrades BeOne Medicines to Buy, Raises Price Target to $380

RBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $451

Truist Securities Maintains Buy on BeOne Medicines, Raises Price Target to $416

Citizens Reiterates Market Outperform on BeOne Medicines, Maintains $396 Price Target

BeOne Medicines Advances Chemotherapy-Free Lymphoma Strategy

BeOne Medicines Announces Topline Results From Its Phase 3 MANGROVE Study Of Foundational BTK Inhibitor Brukinsa Plus Rituximab In Adult Patients With Mantle Cell Lymphoma; Treatment Reduced Risk Of Progression Or Death By 43%

Lai Wang Executes Sell Order: Offloads $295K In BeOne Medicines Stock

Chief Executive Officer At BeOne Medicines Sells $933K Of Stock

President and COO At BeOne Medicines Sells $356K Of Stock

BeOne Medicines Discloses Chinese Tax Settlement Of CNY446M; To Be Noted In Q2 GAAP Financial Results

Lai Wang Executes Sell Order: Offloads $310K In BeOne Medicines Stock

Insider Selling: JOHN OYLER Unloads $980K Of BeOne Medicines Stock

President and COO At BeOne Medicines Sells $361K Of Stock

Insider Decision: Henry Chan Lee Offloads $156K Worth Of BeOne Medicines Stock

Chief Executive Officer Of BeOne Medicines Makes $501K Sale

Sell Alert: Henry Chan Lee Cashes Out $110K In BeOne Medicines Stock